menu search

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Scholar rock: the market isn't enthusiastic despite decent clinical data

Scholar Rock Holding Corp. is developing a growth factor targeted therapy called apitegromab for Spinal Muscular Atrophy. Positive interim data from a...

August 27, 2023, 9:13 am

Exelixis: positive pancreatic cancer data brings 2 big catalysts on deck

phase 3 CABINET study, using CABOMETYX to treat patients with advanced pancreatic cancer and advanced p...

August 27, 2023, 6:03 am

Bitcoin spark: solana’s strongest competitor in the crypto arena

Read our article & learn about Solana’s strongest competitor in the crypto market, Bitcoin Spark (BTCS), which is in its presale ...

August 26, 2023, 5:29 pm

Beyond tesla: 3 electric vehicle stocks you've probably overlooked

Automakers around the world are working overtime to pivot to electric vehicles and phase out gasoline-p...

August 26, 2023, 10:00 am

Biomerica reports fiscal 2023 year end results

Revenues excluding Covid test sales increased 15% for fiscal 2023 vs fiscal 2022 Successfully completed inFoods® IBS pilot program with one of the la...

August 25, 2023, 9:00 pm

Neurocrine needs a meaningful clinical win to break out, and crinecerfont could do it

Neurocrine Biosciences needs a clinical win after years of disappointing results and stagnant stock performance. The upcoming ...

August 25, 2023, 6:01 pm

Evelo biosciences: may be worth a small, highly speculative long position considering upcoming psoriasis phase 2 results

Following recent cash raise, EVLO has enough (barely) cash to the next catalyst, phase 2 readout in pso...

August 25, 2023, 5:08 pm

Werewolf: q4 2023 data readout and enhancement of validated targets

Preliminary safety and biomarker results from the phase 1/1b study, using WTX-124 for the treatment of ...

August 25, 2023, 4:48 pm

Exelixis (exel) late-stage study in pancreatic tumors positive

Exelixis' (EXEL) phase III CABINET study shows dramatic improvement in efficacy in advanced pancreatic ...

August 25, 2023, 1:32 pm

Usdjpy daily analysis – august 25, 2023

USDJPY continues to be entrenched in an uptrend that began at 138.05, with the recent price movements from 146.55 appearing to be a consolidation ...

August 25, 2023, 11:19 am

Merck and eisai cull late-stage study for head and neck cancer therapy

Merck & Co Inc (NYSE:MRK) and research partner Eisai said they are halting a late-stage trial that used a combination of drugs to treat a type of head...

August 25, 2023, 7:58 am

Travere therapeutics to present abstracts at the society for the study of inborn errors of metabolism annual symposium 2023

SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present clinical data fr...

August 24, 2023, 8:30 pm

Travere therapeutics to present abstracts at the society for the study of inborn errors of metabolism annual symposium 2023

SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present clinical data fro...

August 24, 2023, 4:30 pm

Bridgebio pharma to present detailed results from the phase 3 attribute study in patients with transthyretin amyloidosis cardiomyopathy (attr-cm) at european society of cardiology (esc) congress 2023

PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...

August 24, 2023, 4:01 pm

The southport school announces kate haft as director of development

Southport Native to Drive Next phase of Fundraising and Alumni Engagement at School Dedicated to Educat...

August 24, 2023, 3:10 pm

Great lakes (gldd) wins contract for port arthur lng phase 1

With this contract, Great Lakes' (GLDD) backlog and recent pending awardable work now exceed $1 billion....

August 24, 2023, 1:32 pm


Search within

Pages Search Results: